Abivax S.A.
AAVXF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001956827
No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q3 2026; no superinvestor holds it.
Other share classesABVX
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026
- 0
- 13F valueReported value at the end of Q3 2026
- $0
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in EUR.
- Revenue, FY2025
- EUR 4.57M
- −63.3% year over year
- Net income, FY2025
- EUR -336.1M
- No comparable prior period
- Free cash flow, FY2025
- EUR -161.3M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: EUR 336.1M (7354.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 166.6K
- Shares sold short
- Change
- −556.6K
- −77.0% vs. previous
- Days to cover
- > 999
- Above FINRA's cap of 999.99 days
Superinvestors holding AAVXF, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding AAVXF at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Abivax S.A. insiders from Form 4, newest first.
No open-market purchases or sales by Abivax S.A. insiders are on file.
Top 10 13F holders, Q3 2026
View all: Top 10 13F holders, Q3 2026The largest institutional positions in Abivax S.A. at the end of Q3 2026; share changes are against Q2 2026.
No institution reported holding AAVXF in 13F filings for Q3 2026.